ARDX
Biotechnology · Healthcare
Chief Accounting Officer
2020-06-09–present
Chief Accounting Officer
Ardelyx, Inc. (ARDX)Equibles does not estimate personal net worth.
Get an email with a short summary when Zevra Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ZVRA alertsJustin Renz is recorded as CFO at Zevra Therapeutics, Inc. (ZVRA) and Chief Accounting Officer at Ardelyx, Inc. (ARDX) since June 9, 2020. Zevra Therapeutics, Inc. reported in an 8-K filed March 9, 2026 that Justin Renz was appointed principal financial officer, effective March 10, 2026. Zevra Therapeutics, Inc. reported in an 8-K filed March 9, 2026 that Justin Renz was appointed Chief Financial Officer and Treasurer, effective March 9, 2026. The proxy statement of Ardelyx, Inc. reports total compensation of $3,551,684 for Justin Renz in fiscal 2025, including a base salary of $464,434. Disclosed compensation is on record for 4 fiscal years. Justin Renz has spoken on 20 earnings calls and 2 other investor events across 2 companies, most recently for Zevra Therapeutics, Inc. on November 3, 2026. Those appearances were for Ardelyx, Inc. (ARDX) and Zevra Therapeutics, Inc. (ZVRA). Ardelyx, Inc. is classified in the Biotechnology industry within the Healthcare sector. Zevra Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Ardelyx, Inc. includes Michael Raab (CEO and Board Member), Keith Santorelli (CFO), Susan Hohenleitner (CFO) and 7 others.
“On March 4, 2026, the Company appointed Justin Renz as Chief Financial Officer and Treasurer, effective March 9, 2026, and as principal financial officer, effective March 10, 2026.”
“On March 4, 2026, the Company appointed Justin Renz as Chief Financial Officer and Treasurer, effective March 9, 2026, and as principal financial officer, effective March 10, 2026.”
“Before I begin, I want to encourage everyone to refer to our quarterly report on Form 10-Q, which we intend to file later today for more detailed financial information.”
“We are in very good shape, and Neil and the Zebra team have really positioned us well over the last couple of years with the success that we've had. particularly around the MyPleifel launch.”
“We have a regular push and pull with our Chief Commercial Officer, Josh, to find the best use of our treasure we take shareholder money very seriously so we have regular dialogue on sizing of the team efforts to invest we are in the growth stage so you know when we have 260 million dollars on our balance sheet as of…”
“Underpinning our achievements is a strong financial foundation and a robust cash position, which provide the flexibility to invest in commercial execution, advance our pipeline, and pursue future growth opportunities while maintaining financial discipline.”
“In addition to the financial details included in today's call, we encourage you to refer to our quarterly report on Form 10-Q for more detailed information, which we intend to file shortly.”
2020-06-09–present
Proxy statement
Start not stated–2025-04-30
Last confirmed by a filing; no departure on record
Start not stated–2022-04-29
Last confirmed by a filing; no departure on record
ARDX
Biotechnology · Healthcare
Chief Accounting Officer
2020-06-09–present
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Ardelyx, Inc. (ARDX) | Former Chief Financial and Operations Officer | $464,434 | $3,551,684 |
| 2024 | Ardelyx, Inc. (ARDX) | Chief Financial and Operations Officer | $517,000 | $2,983,853 |
| 2021 | Ardelyx, Inc. (ARDX) | Chief Financial Officer | $445,500 | $1,734,063 |
| 2020 | Ardelyx, Inc. (ARDX) | Chief Financial Officer | $242,839 | $1,468,247 |